Skip directly to search Skip directly to A to Z list Skip directly to navigation Skip directly to page options Skip directly to site content

Precision Health Database


Precision Health Database|Search|PHGKB

Last data update: Jun 06, 2023. (Total: 60108 Documents since 2012)
   dataset      
Filtered By:

Previous    

Records 1 - 30 (of 2179 Records)

Next

Query Trace: all[original query]>>Pharmacogenomics[Category]
Addressing barriers to increased adoption of DPYD genotyping at a large multisite cancer center.
Sarah A Morris et al. Am J Health Syst Pharm 2023
Clinical pharmacogenomics implementation in Thailand: a dream come true.
Chonlaphat Sukasem et al. Pharmacogenomics 2023
Profiling of pharmacogenomic variants in CYP2D6 and DPYD in indigenous Arab breast cancer patients.
Abdullah Alsulaiman et al. Pharmacogenomics 2023
A randomized controlled trial of analogue pharmacogenomic testing feedback for psychotropic medications.
John Young et al. PEC Innov 2023 2100119
Effect of CYP2D6 pharmacogenetic phenotype and phenoconversion on serum concentrations of antidepressants and antipsychotics: a retrospective cohort study.
Maike Scherf-Clavel et al. Int J Clin Pharm 2023
Child and adolescent psychiatrists' use, attitudes, and understanding of genetic testing and pharmacogenetics in clinical practice.
Takahiro Soda et al. Psychiatry Res 2023 325115246
Implementation of DPYD Genotyping in Admixed American Populations: Brazil as a Model Case.
Guilherme Suarez-Kurtz et al. Clin Pharmacol Ther 2023
Confirmatory DPYD Testing in Patients Receiving Fluoropyrimidines who are Suspected DPYD Variant Carriers Based on a Genetic Data Repository.
Amy L Pasternak et al. Clin Pharmacol Ther 2023
Impact of transitioning to an active, noninterruptive CYP2C19/proton pump inhibitor alert on prescribing patterns.
Amanda Massmann et al. Am J Health Syst Pharm 2023
The Contribution of Pharmacogenetic Drug Interactions to 90-Day Hospital Readmissions in a Real-World Health System.
Sean David et al. Ann Fam Med 2023 (21(Suppl 1))
Cost-effectiveness of Pharmacogenomic Testing: How to Measure the Value of Having the Right Dose of the Right Drug for the Right Patient
L Shi et al, CDC Blog Post, May 8, 2023
Personalizing neoadjuvant immune-checkpoint inhibition in patients with melanoma
MW Lucas et al, Nat Rev Clin Oncol, May 2023
Knowledge and attitudes of medical and pharmacy students about pharmacogenomics: a systematic review and meta-analysis.
Chen Li et al. Pharmacogenomics J 2023
Patient satisfaction with return of pharmacogenomic results utilizing a patient portal message.
Joel Van Heukelom et al. Pharmacogenomics 2023
Cost-effectiveness analysis of genetic tools to predict treatment response in patients with cystic fibrosis.
Yeva Sahakyan et al. J Cyst Fibros 2023
Impact of pharmacogenomic DPYD variant guided dosing on toxicity in patients receiving fluoropyrimidines for gastrointestinal cancers in a high-volume tertiary centre.
David K Lau et al. BMC Cancer 2023 23(1) 380
A Comprehensive Analysis of 21 Actionable Pharmacogenes in the Spanish Population: From Genetic Characterisation to Clinical Impact.
Rocio Nunez-Torres et al. Pharmaceutics 2023 15(4)
Azole antifungals and inter-individual differences in drug metabolism: the role of pharmacogenomics and precision medicine.
Mohitosh Biswas et al. Expert Opin Drug Metab Toxicol 1-10
Immune Checkpoint Inhibitors - The Need for Innovation.
P Connor Johnson et al. N Engl J Med 388(16) 1529-1532
Implementation of Clinical CYP3A Genotyping for Tacrolimus Dosing in A Large Kidney Transplant Program.
Emma Tillman et al. J Clin Pharmacol 2023
Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6, CYP2C19, CYP2B6, SLC6A4, and HTR2A Genotypes and Serotonin Reuptake Inhibitor Antidepressants.
Chad A Bousman et al. Clinical pharmacology and therapeutics 2023
Exploring the potential benefits of pharmacogenomics in chronic respiratory diseases.
Ingrid Fricke-Galindo et al. Pharmacogenomics 2023
Pharmacogenetics testing (DPYD and UGT1A1) for fluoropyrimidine and irinotecan in routine clinical care: Perspectives of medical oncologists and oncology pharmacists.
Sarah Glewis et al. Journal of oncology pharmacy practice : official publication of the International Society of Oncology Pharmacy Practitioners 2023 10781552231167554
Comparison of targeted vs. expanded pharmacogenomic testing: What are we missing?
Mason Chambal et al. Journal of the American Pharmacists Association : JAPhA 2023
Predicting response to enzalutamide and abiraterone in metastatic prostate cancer using whole-omics machine learning.
Anouk C de Jong et al. Nature communications 2023 14(1) 1968
Metoprolol and CYP2D6: A Retrospective Cohort Study Evaluating Genotype-Based Outcomes.
Savannah Collett et al. Journal of personalized medicine 2023 13(3)
Relevance of Pharmacogenomics to the Safe Use of Antimicrobials.
Ann K Daly et al. Antibiotics (Basel, Switzerland) 2023 12(3)
MicroRNA in the Diagnosis and Treatment of Doxorubicin-Induced Cardiotoxicity.
Ziyu Kuang et al. Biomolecules 2023 13(3)
Pharmacogenetic interactions of medications administered for weight loss in adults: a systematic review and meta-analysis.
Joelle BouSaba et al. Pharmacogenomics 2023
Feasibility of Community Pharmacist-Initiated and Point-of-Care CYP2C19 Genotype-Guided De-Escalation of Oral P2Y12 Inhibitors.
Amar D Levens et al. Genes 2023 14(3)
TOP